HomeCompareROKT vs JNJ

ROKT vs JNJ: Dividend Comparison 2026

ROKT yields 0.34% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ROKT wins by $121.00 in total portfolio value
10 years
ROKT
ROKT
● Live price
0.34%
Share price
$99.46
Annual div
$0.34
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.1K
Annual income
$34.52
Full ROKT calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — ROKT vs JNJ

📍 ROKT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodROKTJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ROKT + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ROKT pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ROKT
Annual income on $10K today (after 15% tax)
$28.70/yr
After 10yr DRIP, annual income (after tax)
$29.34/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, JNJ beats the other by $674.27/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ROKT + JNJ for your $10,000?

ROKT: 50%JNJ: 50%
100% JNJ50/50100% ROKT
Portfolio after 10yr
$20.1K
Annual income
$431.15/yr
Blended yield
2.15%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

ROKT
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ROKT buys
0
JNJ buys
0
No recent congressional trades found for ROKT or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricROKTJNJ
Forward yield0.34%3.36%
Annual dividend / share$0.34$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR0%5.8%
Portfolio after 10y$20.1K$20.0K
Annual income after 10y$34.52$827.78
Total dividends collected$342.00$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ROKT vs JNJ ($10,000, DRIP)

YearROKT PortfolioROKT Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$10,734$33.77$10,676$355.77+$58.00ROKT
2$11,519$33.87$11,407$389.39+$112.00ROKT
3$12,359$33.97$12,198$426.53+$161.00ROKT
4$13,259$34.07$13,056$467.62+$203.00ROKT
5$14,221$34.15$13,987$513.12+$234.00ROKT
6$15,250$34.24$14,998$563.56+$252.00ROKT
7$16,352$34.31$16,098$619.52+$254.00ROKT
8$17,531$34.39$17,295$681.69+$236.00ROKT
9$18,793$34.45$18,599$750.82+$194.00ROKT
10$20,143$34.52$20,022$827.78+$121.00ROKT

ROKT vs JNJ: Complete Analysis 2026

ROKTStock

The State Street SPDR S&P Kensho Final Frontiers ETF seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Kensho Final Frontiers Index (the "Index")Seeks to track an index utilizing artificial intelligence and a quantitative weighting methodology to capture companies whose products and services are driving innovation behind the exploration of the final frontiers, which includes the areas of outer space and the deep seaMay provide an effective way to pursue long-term growth potential by investing in a portfolio of companies involved in the expansion of human understanding and presence in outer space and in the oceans

Full ROKT Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this ROKT vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ROKT vs SCHDROKT vs JEPIROKT vs OROKT vs KOROKT vs MAINROKT vs ABBVROKT vs MRKROKT vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.